Patent HU-T50776-A (HU)
Title: Process for producing substituted pyridine derivatives and pharmaceutical compositions containing them as active components
Inventor: ANGEBAUER ROLF
IPC: C07D405/12
Filed: 1989-01-19
Abstract: Preparation of pyridine derivatives (I) involves: (1) reducing a 5-hydroxymethyl-nicotinic acid derivative (XXII) to the hydroxymethyl derivative; (2) oxidizing to an aldehyde; (3) reacting with diethyl-2-(cyclohexylamino)-vinyl-phosphonate to give a pyridyl-acrolein (IX) and (4) reacting with an alkyl acetoacetate (X). Preparation of pyridine compounds of formula (I) or their oxidation products involves: (1) reducing a 5-hydroxymethylnicotinic acid derivative of formula (XXII) to the hydroxymethyl derivative, using a metal hydride in a solvent at -70 to +100[deg]C; (2) oxidizing the product conventionally to an aldehyde; (3) reacting the product with diethyl 2-(cyclohexylamino)-vinyl-phosphonate in the presence of sodium hydride in a solvent at -20 to + 40[deg]C to give an acrolein derivative of formula (IX); (4) reacting (IX) with an acetoacetate ester of formula (X) in presence of base in a solvent; and (5) optionally saponifying the obtained ester (I) to give an acid, cyclizing the acid to give a lactone, saponifying the ester or lactone to give a salt, hydrogenating the ethylenylene residue (X = CH=CH) to give ethylene (X = CH 2CH 2) and/or separating isomers. [Image] A : heteroaryl or aryl (both optionally substituted (os)), or alkyl; B' : cycloalkyl or alkyl (os); D, E : H, CN, NO 2 or cycloalkyl; alkyl, heteroaryl or aryl (all os); or NR 3R 4, COR 5 or -CR 11R 12-Y, or D + E : -C(O)-Z-(CH 2) m- or -W-Z-CR 13R 14-(CH 2) m- (bonded to adjacent C to complete a fused ring); R 3, R 4H, Q, Ar, Ara, COR 6 or SO 2R 7; or R 3 + R 4alkylidene; Q : alkyl; Ar : aryl; Ara : aralkyl; R 6H, NHR 8 or OQ; or Q, Ar, OAr, Ara, OAra or heteroaryl (all os); R 7cycloalkyl, or Q, Ar, Ara or heteroaryl (all os); R 8H or as R 7; R 5H, cycloalkyl, OH, OQ, trimethylsilylalkoxy, OAr, OAra or NR 9R 10, or pyrrolidino, piperidino, morpholino, thiomorpholino or piperazino (all os); R 11, R 12H, Q (os) or cycloalkyl, or CR 11R 12a ring; Y : NR 13R 14, COR 15, SR 16, SOR 16, SO 2R 16, OR 17 or N 3; R 13, R 14H, Q, COR 15 or SO 2R 16; or Ar or Ara (both os), or R 13 + R 14alkylene; R 15H, NR 18R 19, Q or OQ; or Ar, OAr, Ara, OAra or heteroaryl (all os); R 16cycloalkyl; Q (os); Ar, Ara or heteroaryl (all os); or SiMe 3, SiMe 2Et or NR 9R 10; R 17H or cycloalkyl; alkyl, aryl or heteroaryl (all os); or 2,5-dioxo-tetrahydropyrryl, tetrahydropyranyl, SiQ 3 or COR 16; R 18, R 19H or cycloalkyl; or Q, Ar, Ara or heteroaryl (all os); W : CO or CH(OH); m : 1-3; Z : O, S, CH 2 or NR 20; R 20H, Q, Ar, CONH 2 or COOQ; X : CH 2CH 2 or CH=CH; R : optionally lactonized 4-carboxy-1,3-dihydroxybutyl derivative group of formula (a) or (b); R 21H or Q; R 22H, Q, Ar, Ara or cation; R 17'H, 1-3C alkyl, butyl, isobutyl, tert. butyl, pentyl, isopentyl, hexyl or isohexyl; R 23Q; R 241-4C alkyl. [Image] The full definitions are given in the 'DEFINITIONS - Full Definitions' field. An independent claim is included for (I) prepared by the process. ACTIVITY : Antilipemic; antiarteriosclerotic. MECHANISM OF ACTION : Cholesterol biosynthesis inhibitor; 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor. No biological data is given.